In severe pneumonia triggered by SARS-CoV-2 infection
Recruitment start for the ProTrans study for treatment of COVID-19
NextCell Pharma AB (“NextCell”) announces today that the Swedish COVID-19 stuy has been initiated and is now ready to include patients with severe pneumonia triggered by SARS-CoV-2 infection. The treatment is aimed at patients who are hospitalized and with a high risk of needing ventilatory support. ProTrans is given as a peripheralinfusion. With the aim of reducing hyper-inflammation within the lungs. The goal of the treatment is to shorten hospital stay and time for rehabilitation and save lifes.
The study will be performed at the University Hospital in Örebro in collaboration with the Department of Clinical Trials and Karolinska Trial Alliance. The Principal Investigator in Sweden is Professor Josefin Sundh.
The study title is: “Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton’s Jelly – Umbilical Cord Mesenchymal Stromal Cells (ProTrans®): Open Phase IB Clinical Trial” NextCell sponsors the study, which will include nine patients with severe pneumonia and confirmed COVID-19 (SARS-CoV-2) infection, who will be treated with low (three patients), medium (three patients), or high dose (three patients) ProTrans.
The study is registered on clinicaltrials.gov with number NCT04896853.
Stay up to date with the latest development in NextCell Pharma
For more information about NextCell Pharma AB, please contact:
Mathias Svahn, CEO
Sofia Fredrikson, CFO
Phone: 08-735 5595
About NextCell Pharma AB
NextCell is a Phase II cell therapy company with the lead candidate ProTrans™, for the treatment of type-1 diabetes. Focus is to take ProTrans™ to market approval via a phase III study. Furthermore, NextCell operates Cellaviva, Scandinavia’s largest stem cell bank for family-saving of stem cells from umbilical cord blood and umbilical cord tissue with permission from IVO.